The efficacy of ONC‐212 under conditions that mimic the TME and against TP53 dysfunctional CLL cells raises the possibility that this treatment approach may be particularly effective in patients with a poor prognosis or for patients who develop disease resistant to BCR or BCL2‐targeted therapies. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.